EUVIMEDEUVIMED entdecken
Crossref

The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae

Xiaotuan Zhang iD, Weiliang Zeng, Jingchun Kong, Zeyu Huang, Hongyun Shu, Miran Tang, Changrui Qian, Chunquan Xu, Tieli Zhou iD, Jianzhong Ye

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Xiaotuan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affilia…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, beta-Lactamases, Ceftazidime. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Scientific Research Project of Department of Education of Zhejiang Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the prevalence and mechanisms of ceftazidime/avibactam heteroresistance in KPC-producing Klebsiella pneumoniae (KPC-KP) isolates, as well as the role of heteroresistance in the transition of ceftazidime/avibactam susceptibility to resistance.

Methods

Clinical KPC-KP isolates were obtained from a tertiary hospital in China from 2016 to 2017 and 2019 to 2020. Antimicrobial susceptibility was determined by the broth microdilution method. Population analysis profiles were used to assess ceftazidime/avibactam heteroresistance. WGS and molecular cloning were conducted to reveal heteroresistance mechanisms and molecular characteristics.

Results

The findings indicated that the transition of ceftazidime/avibactam susceptibility to resistance during the treatment of KPC-KP infection is primarily attributed to the heteroresistance exhibited by KPC-KP isolates towards ceftazidime/avibactam. Among 355 ceftazidime/avibactam-susceptible KPC-KP isolates (indicating a resistance rate of 0%), 41 (11.55%) exhibited ceftazidime/avibactam heteroresistance, with the primary mechanism being the presence of KPC mutant subpopulations. These KPC variants, arising from point mutations, deletions and insertions, significantly increased ceftazidime/avibactam resistance while alongside enhanced carbapenem susceptibility. Notably, 11 new KPC variants were identified. Furthermore, four heteroresistant isolates were caused by mixed infection involving subpopulations carrying NDM-1 or NDM-5. Phylogenetic analysis indicated that the clonal spread of ST11-KL64 KPC-KP may be correlated with the prevalence of heteroresistance.

Conclusions

Ceftazidime/avibactam heteroresistance, primarily driven by pre-existing KPC variants, underscores the importance of considering heteroresistance in ceftazidime/avibactam therapeutics. Awareness of these dynamics is crucial for the effective and sustainable clinical application of ceftazidime/avibactam.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug Resistance, Multiple, BacterialKlebsiella pneumoniaeHumansBacterial ProteinsChinaDrug CombinationsKlebsiella InfectionsMicrobial Sensitivity TestsPrevalenceWhole Genome Sequencing

Substanzen

Anti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCeftazidimeDrug Combinations

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province…
  • Department of Medical Lab Science, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.

ORCID-Profile: Xiaotuan Zhang, Tieli Zhou

Förderung

  • Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province
  • Scientific Research Project of Department of Education of Zhejiang Province of China

Zitieren

APA

Zhang, X., Zeng, W., Kong, J., Huang, Z., Shu, H., Tang, M., Qian, C., Xu, C., Zhou, T., & Ye, J. (2024). The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae174

Vancouver

Zhang X, Zeng W, Kong J, Huang Z, Shu H, Tang M, et al. The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae174

BibTeX
@article{Zhang2024,
  author = {Zhang, Xiaotuan and Zeng, Weiliang and Kong, Jingchun and Huang, Zeyu and Shu, Hongyun and Tang, Miran and Qian, Changrui and Xu, Chunquan and Zhou, Tieli and Ye, Jianzhong},
  title = {The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae174}
}
Kostenlos starten →